IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Time to Sell?

IPSEN (OTCMKTS:IPSEY) shares gapped down prior to trading on Monday. The stock had previously closed at $41.8975, but opened at $39.40. IPSEN shares last traded at $39.75, with a volume of 9,640 shares.

Analyst Upgrades and Downgrades

Several analysts recently commented on IPSEY shares. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Jefferies Financial Group downgraded shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Finally, Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 17th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

IPSEN Stock Down 5.1%

The company has a fifty day moving average price of $45.72 and a 200-day moving average price of $46.44.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on the discovery, development and commercialization of medicines in specialty care. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with an emphasis on treatments for conditions that often have limited therapeutic options.

The company’s portfolio includes Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected movement disorders and aesthetic applications, and cancer treatments such as Cabometyx and Onivyde.